Intrinsiqq
Lemaitre Vascular Inc. logo

Lemaitre Vascular Inc. Quality Score

LMAT

⊜ Compare
Quality72

Growth remains strong (avg 100/100), but valuation is pulling the composite down (avg 50/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
30.7x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
60/100
27.2x

25–30x, paying up for cash generation

Revenue Growth
100/100
12.9%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
35.1%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
10.6%

Heavy dilution above 5%

Margin Trend
100/100
+12.9pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$186M

Net cash position, no leverage concern

2022
$83.0M
$17.0M
2023
$105M
$19.0M
2024
$300M
$186M
2025
$359M
$186M
TTM
$376M
$190M
CashDebt
Return on Capital
40/100
9.9%

8–10%, clearing the bar

Customize WeightsPremiumUpgrade

Lemaitre Vascular (LMAT) quality: score, margins and returns

Lemaitre Vascular (LMAT) scores 72/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 29.5% operating margins and 9.9% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Lemaitre Vascular (LMAT) a high-quality business?+

Lemaitre Vascular scores 72 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 29.5% operating margin and a 9.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Lemaitre Vascular's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LMAT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lemaitre Vascular scores well and where it falls behind.

What is Lemaitre Vascular's return on invested capital (ROIC)?+

Lemaitre Vascular earns about 9.9% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LMAT's margins and growth on this scorecard to judge durability.

How profitable is Lemaitre Vascular?+

Lemaitre Vascular runs an operating margin of about 29.5% and a net margin of about 25.0%. Revenue has grown at roughly 14.0% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 2 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 3 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with LMAT

CompareIntrinsic value
KIDSOrthoPediatrics Corp.
$33.51+6.69%45
SKINSkinHealth Systems Inc.
$11.05+6.76%42
CERSCerus Corporation
$2.42+3.21%32
SIBNSi-Bone Inc.
$24.95+4.96%40
HTFLHeartFlow, Inc.
$56.57+3.99%49
TMCITreace Medical Concepts, Inc.
$4.50+5.14%14
ANGOAngiodynamics Inc.
$12.27+4.60%40
PRCTProcept BioRobotics Corporation
$21.66+7.39%40

Held by ETFs

LMAT is in 72 US ETFs. The largest of them, with LMAT's weight in each:

Spot a number that looks wrong? Check it in LMAT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LMAT

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.